within Pharmacolibrary.Drugs.ATC.C;

model C09CA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.18,
    Cl             = 0.23666666666666666,
    adminDuration  = 600,
    adminMass      = 0.06,
    adminCount     = 1,
    Vd             = 0.141,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011833333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Fimasartan is an angiotensin II receptor antagonist (ARB) used for the treatment of hypertension, helping to lower blood pressure and reduce the risk of cardiovascular events. It is approved and used in several countries, particularly in South Korea.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Kim, TH, et al., &amp; Shin, BS (2014). Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 44(10) 913–925. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2014.915359&quot;>10.3109/00498254.2014.915359</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24786684/&quot;>https://pubmed.ncbi.nlm.nih.gov/24786684</a></p></li><li><p>Chi, YH, et al., &amp; Kim, SL (2011). Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. <i>American journal of cardiovascular drugs : drugs, devices, and other interventions</i> 11(5) 335–346. DOI:<a href=&quot;https://doi.org/10.2165/11593840-000000000-00000&quot;>10.2165/11593840-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21910510/&quot;>https://pubmed.ncbi.nlm.nih.gov/21910510</a></p></li><li><p>Angeli, F, et al., &amp; Reboldi, G (2018). PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives. <i>Expert opinion on drug metabolism &amp; toxicology</i> 14(5) 533–541. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2018.1468435&quot;>10.1080/17425255.2018.1468435</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29676941/&quot;>https://pubmed.ncbi.nlm.nih.gov/29676941</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09CA10;
